Business

Biophytis S A : unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia

Biophytis S A : unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and

Biophytis SaSeptember 11, 20255

About this update from Biophytis Sa

11 Sep 2025 07:00 CEST Subscribe Issuer BIOPHYTIS See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo 16165_1357435_PR_Detailed_Plan_SARA_VDEF.pdf Source Biophytis Provider Les Echos Company Name BIOPHYTIS ISIN FR001400OLP5 Symbol ALBPS Market Euronext Growth

View stock analysis, news, and events for Biophytis Sa

Biophytis S A : unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia

About this update from Biophytis Sa

More from Biophytis Sa

Biophytis S A : ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY

Biophytis S A : to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity